Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Anne, Aunins"'
Autor:
Patrick Yassini, Mark Hutchens, Yamuna D. Paila, Lorraine Schoch, Anne Aunins, Uma Siangphoe, Robert Paris
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 19, Iss 1 (2023)
This interim analysis of an ongoing phase 1 randomized clinical trial evaluated the safety, reactogenicity, and immunogenicity of mRNA-1283, a next-generation SARS-CoV-2 messenger RNA (mRNA)-based vaccine encoding two segments of the spike protein (i
Externí odkaz:
https://doaj.org/article/50de6aeace75428fabfaf868ecf2e340
Autor:
Xiaoying, Shen, Spyros, Chalkias, Jing, Feng, Xing, Chen, Honghong, Zhou, Jean-Claude, Marshall, Bethany, Girard, Joanne E, Tomassini, Anne, Aunins, Rituparna, Das, David C, Montefiori
Publikováno v:
New England Journal of Medicine. 387:1234-1236
Autor:
Evan J, Anderson, C Buddy, Creech, Vladimir, Berthaud, Arin, Piramzadian, Kimball A, Johnson, Marcus, Zervos, Fredric, Garner, Carl, Griffin, Khozema, Palanpurwala, Mark, Turner, Jeffrey, Gerber, Richard L, Bennett, Kashif, Ali, Madhavi, Ampajwala, Gary, Berman, Jennifer, Nayak, Carey, Chronis, Barbara, Rizzardi, William J, Muller, Christopher A, Smith, George, Fuchs, Daniel, Hsia, Joanne E, Tomassini, Dianne, DeLucia, Caroline, Reuter, Barbara, Kuter, Xiaoping, Zhao, Weiping, Deng, Honghong, Zhou, Daniela, Ramirez Schrempp, Kelly, Hautzinger, Bethany, Girard, Karen, Slobod, Roderick, McPhee, Rolando, Pajon, Anne, Aunins, Rituparna, Das, Jacqueline M, Miller, Sabine, Schnyder Ghamloush, Yamna, Ali
Publikováno v:
The New England journal of medicine. 387(18)
The safety, reactogenicity, immunogenicity, and efficacy of the mRNA-1273 coronavirus disease 2019 (Covid-19) vaccine in young children are unknown.Part 1 of this ongoing phase 2-3 trial was open label for dose selection; part 2 was an observer-blind
Autor:
Patrick Yassini, Mark Hutchens, Yamuna D. Paila, Lorraine Schoch, Anne Aunins, Uma Siangphoe, Robert Paris
BackgroundThis interim analysis of an ongoing phase I randomized clinical trial evaluated the safety, reactogenicity, and immunogenicity of mRNA-1283, a next-generation SARS-CoV-2 messenger RNA (mRNA)-based vaccine encoding 2 segments of the spike pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0509b783ad78b40ae5174866d4737e66
https://doi.org/10.1101/2022.10.18.22281050
https://doi.org/10.1101/2022.10.18.22281050
Autor:
Rolando Pajon, Nicole A. Doria-Rose, Xiaoying Shen, Stephen D. Schmidt, Sijy O’Dell, Charlene McDanal, Wenhong Feng, Jin Tong, Amanda Eaton, Maha Maglinao, Haili Tang, Kelly E. Manning, Venkata-Viswanadh Edara, Lilin Lai, Madison Ellis, Kathryn M. Moore, Katharine Floyd, Stephanie L. Foster, Christine M. Posavad, Robert L. Atmar, Kirsten E. Lyke, Tongqing Zhou, Lingshu Wang, Yi Zhang, Martin R. Gaudinski, Walker P. Black, Ingelise Gordon, Mercy Guech, Julie E. Ledgerwood, John N. Misasi, Alicia Widge, Nancy J. Sullivan, Paul C. Roberts, John H. Beigel, Bette Korber, Lindsey R. Baden, Hana El Sahly, Spyros Chalkias, Honghong Zhou, Jing Feng, Bethany Girard, Rituparna Das, Anne Aunins, Darin K. Edwards, Mehul S. Suthar, John R. Mascola, David C. Montefiori
Publikováno v:
medRxiv
The Omicron variant of SARS-CoV-2 is raising concerns because of its increased transmissibility and potential for reduced susceptibility to antibody neutralization. To assess the potential risk of this variant to existing vaccines, serum samples from
Publikováno v:
Journal of Membrane Science. 161:171-184
The optimization of a membrane purification step to remove unreacted polysaccharide from a protein–polysaccharide conjugate is described. A key component in this work was the introduction of membrane backpulsing to reduce membrane fouling. The back